<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532880</url>
  </required_header>
  <id_info>
    <org_study_id>18-195</org_study_id>
    <nct_id>NCT03532880</nct_id>
  </id_info>
  <brief_title>A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of a new medication, Olaparib, combined with&#xD;
      radiation therapy for participants with small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of olaparib in combination with low dose thoracic radiotherapy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of olaparib in combination with low dose thoracic radiotherapy by evaluating participant toxicities and adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>For safety, all adverse events as determined by the investigator using CTCAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill 50 mg</intervention_name>
    <description>Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.&#xD;
Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill 100 mg</intervention_name>
    <description>Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.&#xD;
Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill 150 mg</intervention_name>
    <description>Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.&#xD;
Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill 200 mg</intervention_name>
    <description>Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.&#xD;
Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill 250 mg</intervention_name>
    <description>Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.&#xD;
Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill 300 mg</intervention_name>
    <description>Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.&#xD;
Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.</description>
    <arm_group_label>Participants with Small Cell Lung Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological documented diagnosis of SCLC confirmed by a MSKCC pathologist.&#xD;
&#xD;
          -  Documented extensive disease, defined as any tumor beyond the above limited disease&#xD;
             definition, including ipsilateral lung metastases and malignant pleural effusion&#xD;
&#xD;
          -  Completion of induction chemotherapy with a minimum of 4 and no more than 6 cycles of&#xD;
             a platinum agent and etoposide within 8 weeks of trial initiation.&#xD;
&#xD;
          -  No disease progression (i.e.SD or better response per treating physician descretion)&#xD;
             at the completion of chemotherapy.&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Intrathoracic disease should be encompassable in acceptable radiation fields per&#xD;
             investigator clinical judgement.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnosfsky&#xD;
             Performance Score (KPS) &gt;/= 70&#xD;
&#xD;
          -  Patients must have adequately recovered from any adverse events associated with prior&#xD;
             immune-chemotherapy&#xD;
&#xD;
          -  Adequate organ and marrow function, including:&#xD;
&#xD;
               1. Haemoglobin &gt;/= 8.0 g/dL with no blood transfusion in the past 28 days.&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) &gt;/= 1.5 x 10^9/L.&#xD;
&#xD;
               3. Platelet count &gt;/= 100 x 10^9/L.&#xD;
&#xD;
               4. Total bilirubin &lt;/= 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT))&#xD;
                  / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT))&#xD;
                  &lt;/= 2.5 x institutional upper limit of normal unless liver metastases are present&#xD;
                  in which case they must be &lt;/= 5x ULN.&#xD;
&#xD;
               6. Patients must have creatinine clearance estimated using the Cockcroft-Gault&#xD;
                  equation of &gt;/= 51 mL/min&#xD;
&#xD;
          -  Patients must have a life expectancy &gt;/= 16 weeks.&#xD;
&#xD;
          -  Postmenopausal or evidence of non-childbearing status for women of childbearing&#xD;
             potential: negative serum pregnancy test within 28 days of study treatment and&#xD;
             confirmed prior to treatment on day 1.&#xD;
&#xD;
             a. Postmenopausal is defined as any one or more of the following: i. Age &gt;/= 60 years.&#xD;
             ii. Age &lt; 60 and amenorrheic for 1 year or more in the absence of chemotherapy and/or&#xD;
             hormonal treatment.&#xD;
&#xD;
        iii. Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post&#xD;
        menopausal range for women under 60.&#xD;
&#xD;
        iv. Radiation-induced oophorectomy with last menses &gt;1 year ago v. Chemotherapy-induced&#xD;
        menopause with &gt; 1 year interval since last menses. vi. Surgical sterilisation (bilateral&#xD;
        oophorectomy or hysterectomy).&#xD;
&#xD;
          -  Men and women of childbearing potential must be willing to us two highly effective&#xD;
             forms of contraception while on treatment and for at least 3 months after last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated brain metastases.&#xD;
&#xD;
          -  Pneumonitis&#xD;
&#xD;
          -  Previous radiotherapy to thorax (prior breast RT is permitted).&#xD;
&#xD;
          -  Patient is not a candidate for or declines consolidative thoracic radiotherapy.&#xD;
&#xD;
          -  Patients receiving any systemic chemotherapy or thoracic radiotherapy within 3 weeks&#xD;
             prior to study treatment.&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site).&#xD;
&#xD;
          -  Previous enrolment in the present study.&#xD;
&#xD;
          -  Exposure to an investigational product within 30 days or 5 half lives (whichever is&#xD;
             longer) prior to start of the current study drug.&#xD;
&#xD;
          -  Any previous treatment with PARP inhibitor, including olaparib, for the treatment of&#xD;
             small cell lung cancer&#xD;
&#xD;
          -  Resting ECG with QTc &gt; 470 msec on 2 or more time points within a 24 hour period or a&#xD;
             documented family history of long QT syndrome.&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin,&#xD;
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,&#xD;
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg.&#xD;
             ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout&#xD;
             period prior to starting olaparib is 2 weeks.&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A inducers (eg. phenobarbital, enzalutamide,&#xD;
             phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's&#xD;
             Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required&#xD;
             washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital&#xD;
             and 3 weeks for other agents.&#xD;
&#xD;
          -  For patients who have received prior immunotherapy, treatment must be held from 10&#xD;
             days prior to protocol treatment until 10 days after completing protocol treatment.&#xD;
&#xD;
          -  Persistent toxicities (&gt;Common Terminology Criteria for Adverse Event (CTCAE) grade 2)&#xD;
             caused by previous cancer therapy, excluding alopecia.&#xD;
&#xD;
          -  Patients with myelodysplastic syndrome/acute leukaemia or with features suggestive&#xD;
             thereof.&#xD;
&#xD;
          -  Major surgery within 2 weeks of study treatment initiation and patients must have&#xD;
             recovered from any effects of any major surgery.&#xD;
&#xD;
          -  Patients considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, non-malignant systemic disease or active/uncontrolled infection. Examples&#xD;
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3&#xD;
             months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal&#xD;
             cord compression, superior vena cava syndrome, extensive interstitial bilateral lung&#xD;
             disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder&#xD;
             that prohibits obtaining informed consent.&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study&#xD;
             medication.&#xD;
&#xD;
          -  Breast feeding women.&#xD;
&#xD;
          -  Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Patients with a known hypersensitivity to olaparib or any of the excipients of the&#xD;
             product&#xD;
&#xD;
          -  Patients with known active hepatitis (i.e. Hepatitis B or C) due to risk of&#xD;
             transmitting the infection through blood or other body fluids.&#xD;
&#xD;
          -  Previous allogenic bone marrow transplant or double umbilical cord blood&#xD;
             transplantation (dUCBT).&#xD;
&#xD;
          -  Whole blood transfusions in the last 120 days prior to entry to the study (packed red&#xD;
             blood cells and platelet transfusions are acceptable, for timing refer to inclusion&#xD;
             criteria number 8)&#xD;
&#xD;
          -  Other malignancy within the last 5 years except: early stage cutaneous melanoma,&#xD;
             adequately treated non-melanomatous skin cancer, curatively treated in situ cervical&#xD;
             cancer, ductal carcinoma in situ (DCIS), FIGO Grade 1 endometrial carcinoma, or other&#xD;
             solid tumours including lymphomas (without bone marrow involvement) curatively treated&#xD;
             with no evidence of disease for &gt;/= 5 years. Patients with a history of localised&#xD;
             triple negative breast cancer may be eligible, provided they completed their adjuvant&#xD;
             chemotherapy more than three years prior to registration, and that the patient remains&#xD;
             free of recurrent or metastatic disease&#xD;
&#xD;
          -  Absence of brain metastases is not required. Patients must not have symptomatic brain&#xD;
             metastatic disease. The patient may be symptomatically controlled on a stable dose of&#xD;
             corticosteroids before and during the study as long as these were started at least 4&#xD;
             weeks prior to treatment.&#xD;
&#xD;
          -  Patients with spinal cord compression unless considered to have received definitive&#xD;
             treatment for this and evidence of clinically stable disease for 28 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Rimner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Rimner, MD</last_name>
    <phone>212-639-6025</phone>
    <email>rimnera@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Offin, MD</last_name>
    <phone>646-449-1778</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist Alliance Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupesh Kotecha, MD</last_name>
      <phone>786-596-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Olaparib</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>18-195</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

